Literature DB >> 11579422

Mitochondria and degenerative disorders.

M Orth1, A H Schapira.   

Abstract

In mammalian cells, mitochondria provide energy from aerobic metabolism. They play an important regulatory role in apoptosis, produce and detoxify free radicals, and serve as a cellular calcium buffer. Neurodegenerative disorders involving mitochondria can be divided into those caused by oxidative phosphorylation (OXPHOS) abnormalities either due to mitochondrial DNA (mtDNA) abnormalities, e.g., chronic external ophthalmoplegia, or due to nuclear mutations of OXPHOS proteins, e.g., complex I and II associated with Leigh syndrome. There are diseases caused by nuclear genes encoding non-OXPHOS mitochondrial proteins, such as frataxin in Friedreich ataxia (which is likely to play an important role in mitochondrial-cytosolic iron cycling), paraplegin (possibly a mitochondrial ATP-dependent zinc metalloprotease of the AAA-ATPases in hereditary spastic paraparesis), and possibly Wilson disease protein (an abnormal copper transporting ATP-dependent P-type ATPase associated with Wilson disease). Huntingon disease is an example of diseases with OXPHOS defects associated with mutations of nuclear genes encoding non-mitochondrial proteins such as huntingtin. There are also disorders with evidence of mitochondrial involvement that cannot as yet be assigned. These include Parkinson disease (where a complex I defect is described and free radicals are generated from dopamine metabolism), amyotrophic lateral sclerosis, and Alzheimer disease, where there is evidence to suggest mitochondrial involvement perhaps secondary to other abnormalities. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579422     DOI: 10.1002/ajmg.1425

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  78 in total

1.  Learning cell biology as a team: a project-based approach to upper-division cell biology.

Authors:  Robin Wright; James Boggs
Journal:  Cell Biol Educ       Date:  2002

2.  Maternal family history is associated with Alzheimer's disease biomarkers.

Authors:  Robyn A Honea; Eric D Vidoni; Russell H Swerdlow; Jeffrey M Burns
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 3.  Synapses and Sisyphus: life without paraplegin.

Authors:  Harris A Gelbard
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

Review 4.  Neuronal degeneration and mitochondrial dysfunction.

Authors:  Eric A Schon; Giovanni Manfredi
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

Review 5.  Is the transportation highway the right road for hereditary spastic paraplegia?

Authors:  Andrew H Crosby; Christos Proukakis
Journal:  Am J Hum Genet       Date:  2002-09-24       Impact factor: 11.025

6.  Increased mitochondrial permeability in response to intrastriatal N-methyl-D-aspartate: detection based on accumulation of radiolabel from [3H]deoxyglucose.

Authors:  Emad Zaidan; Michael Nilsson; Neil R Sims
Journal:  Neurochem Res       Date:  2004-03       Impact factor: 3.996

7.  Genetic ablation of the p66Shc adaptor protein reverses cognitive deficits and improves mitochondrial function in an APP transgenic mouse model of Alzheimer's disease.

Authors:  R Derungs; G G Camici; R D Spescha; T Welt; C Tackenberg; C Späni; F Wirth; A Grimm; A Eckert; R M Nitsch; L Kulic
Journal:  Mol Psychiatry       Date:  2016-07-19       Impact factor: 15.992

8.  MGARP regulates mouse neocortical development via mitochondrial positioning.

Authors:  Liyun Jia; Tong Liang; Xiaoyan Yu; Chao Ma; Shuping Zhang
Journal:  Mol Neurobiol       Date:  2013-12-10       Impact factor: 5.590

9.  Structural insights into oligomerization and mitochondrial remodelling of dynamin 1-like protein.

Authors:  Chris Fröhlich; Stefan Grabiger; David Schwefel; Katja Faelber; Eva Rosenbaum; Jason Mears; Oliver Rocks; Oliver Daumke
Journal:  EMBO J       Date:  2013-04-12       Impact factor: 11.598

10.  Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage.

Authors:  Rosilla F Bachmann; Yun Wang; Peixiong Yuan; Rulun Zhou; Xiaoxia Li; Salvatore Alesci; Jing Du; Husseini K Manji
Journal:  Int J Neuropsychopharmacol       Date:  2009-01-19       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.